急性胰臟炎市场规模、份额和成长分析（按诊断、病因、治疗、最终用户和地区划分）—产业预测，2026-2033年

预计到 2024 年，全球急性胰臟炎市场规模将达到 61.4 亿美元，到 2025 年将达到 65 亿美元，到 2033 年将达到 102.9 亿美元，在预测期（2026-2033 年）内，复合年增长率为 5.9%。

全球急性胰臟炎市场涵盖了这种以急性胰臟发炎为特征的严重的诊断、治疗和管理。推动市场成长的因素包括急性胰臟炎盛行率的上升、诊断技术的进步以及创新治疗方法的涌现。肥胖、饮酒、胆结石和某些药物等风险因素的增加，进一步加剧了该疾病在全球的发生率。在这个竞争激烈的市场中，众多製药公司、医疗设备製造商和医疗保健服务提供者正在开发和推广尖端解决方案。主要企业正专注于临床试验、建立合作伙伴关係和策略合作，以扩大产品和服务范围并巩固市场地位。这个充满活力的市场旨在提供有效的护理解决方案，以应对与急性胰臟炎相关的复杂挑战。

全球急性胰臟炎市场成长要素

由于多种相互关联的因素，全球急性胰臟炎市场预计将迎来显着成长。糖尿病患者数量的显着增加预计将是推动市场成长的重要因素，因为胰臟炎会损害胰臟中产生胰岛素的细胞，从而增加患者罹患糖尿病的风险。此外，人口老化以及政府为提高公众对胰臟炎的认识而采取的主导，预计也将推动市场需求。消费者生活方式的改变和政府的支持性政策也将对市场扩张起到关键作用。此外，肥胖症和胰臟癌发病率的上升预计也将进一步加速市场成长。

全球急性胰臟炎市场阻碍因素

由于面临许多重大挑战，全球急性胰臟炎市场预计将成长缓慢。治疗费用不断上涨严重阻碍了患者获得治疗的机会，尤其是在医疗资源有限的发展中地区。此外，严格的法规环境也使得新治疗方法和新技术的引入更加复杂，进一步限制了市场扩张。同时，报销体係不完善以及公众对该疾病的认知度较低也是阻碍因素。这些因素综合起来，可能会阻碍市场发展，并限制急性胰臟炎治疗领域的成长机会。

全球急性胰臟炎市场趋势

全球急性胰臟炎市场正经历着变革性的趋势，其核心在于透过各种创新策略改善患者预后。目前，医疗产业正大力推动早期诊断和早期疗育，医疗专业人员优先使用先进的诊断工具，以便在适当的时机启动治疗。此外，个人化医疗的兴起正在改变治疗格局，其驱动力是基因分析和分子诊断技术，这些技术能够根据每位患者的个别特征量身定制治疗方案。这一趋势促进了针对急性胰臟炎独特基因突变的标靶治疗的研发。同时，数位医疗解决方案和微创介入治疗的整合也日益增强，这些措施共同旨在简化患者管理流程并提高康復率。总而言之，这些市场趋势反映了医疗产业致力于提升急性胰臟炎治疗品质的决心。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管环境
• 案例研究
• 技术进步

全球急性胰臟炎市场规模（按诊断和复合年增长率划分）（2026-2033 年）

• 影像检查
• 实验室测试

全球急性胰臟炎市场规模（依病因及复合年增长率划分）（2026-2033 年）

• 胆结石
• 酒精
• 其他的

全球急性胰臟炎市场规模（按治疗方法和复合年增长率划分）（2026-2033 年）

• 静脉输液
• 营养支持
• 止痛药
• 内视镜逆行性胰造影（ERCP）
• 其他的

全球急性胰臟炎市场规模（依最终用户划分）及复合年增长率（2026-2033 年）

• 医院
• 诊所
• 诊断中心
• 其他的

全球急性胰臟炎市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• Pfizer Inc.（United States）
• Merck & Co., Inc.（United States）
• Baxter International Inc.（United States）
• Abbott Laboratories（United States）
• B. Braun SE（Germany）
• CalciMedica Inc.（United States）
• Dynavax Technologies Corporation（United States）
• Fresenius SE & Co. KGaA（Germany）
• GlaxoSmithKline plc（United Kingdom）
• Olympus Corporation（Japan）
• SCM Lifescience（South Korea）
• Samsung Bioepis（South Korea）
• GNT Pharma Co.（South Korea）
• Medtronic plc（Ireland）
• Boston Scientific Corporation（United States）
• Takeda Pharmaceuticals（Japan）
• Novartis AG（Switzerland）
• AbbVie Inc.（United States）
• General Electric Company（United States）
• Mitsubishi Tanabe Pharma Corporation（Japan）

结论与建议

Global Acute Pancreatitis Market size was valued at USD 6.14 Billion in 2024 and is poised to grow from USD 6.5 Billion in 2025 to USD 10.29 Billion by 2033, growing at a CAGR of 5.9% during the forecast period (2026-2033).

The global acute pancreatitis market encompasses the landscape surrounding the diagnosis, treatment, and management of this severe condition characterized by sudden pancreatic inflammation. Several factors stimulate market growth, including the rising prevalence of acute pancreatitis, advancements in diagnostic methodologies, and the emergence of innovative treatment alternatives. Heightened risk factors such as obesity, alcohol use, gallstones, and certain medications further exacerbate the condition's incidence worldwide. The market is notably competitive, with numerous pharmaceutical companies, medical device manufacturers, and healthcare providers engaged in the development and commercialization of cutting-edge solutions. Key players are focusing on clinical trials, partnerships, and strategic collaborations to expand their offerings and enhance market position. This dynamic market aims to provide effective care solutions to address the complexities associated with acute pancreatitis.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Pancreatitis market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acute Pancreatitis Market Segments Analysis

Global Acute Pancreatitis Market is segmented by Diagnosis, Cause, Treatment, End user and region. Based on Diagnosis, the market is segmented into Imaging Tests and Laboratory Tests. Based on Cause, the market is segmented into Gallstones, Alcohol and Others. Based on Treatment, the market is segmented into Intravenous fluid, Nutritional support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP) and Others. Based on End user, the market is segmented into Hospitals, Clinics, Diagnostic Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acute Pancreatitis Market

The Global Acute Pancreatitis market is poised for significant growth due to several interrelated factors. A notable rise in diabetes cases is expected to contribute, as pancreatitis can impair insulin-producing cells in the pancreas, leading to increased diabetes risk among affected individuals. Furthermore, an aging population coupled with heightened government initiatives aimed at raising awareness about pancreatitis is likely to bolster market demand. The influence of evolving consumer lifestyles, along with supportive government policies, will also play a pivotal role in market expansion. Additionally, the rising prevalence of obesity and pancreatic cancer will further propel the market's growth trajectory.

Restraints in the Global Acute Pancreatitis Market

The Global Acute Pancreatitis market is expected to experience sluggish growth due to a range of significant challenges. High treatment costs significantly hinder accessibility, particularly in developing regions where healthcare facilities may be limited. Furthermore, a stringent regulatory landscape complicates the introduction of new therapies and technologies, creating additional barriers to market expansion. Additionally, inadequate reimbursement practices and a general lack of public awareness about the condition further contribute to the constraints faced by the industry. Together, these factors are likely to impede the market's development and limit opportunities for growth in the treatment of acute pancreatitis.

Market Trends of the Global Acute Pancreatitis Market

The global acute pancreatitis market is witnessing transformative trends that focus on enhancing patient outcomes through various innovative strategies. A significant shift towards early diagnosis and intervention is emerging, with healthcare professionals emphasizing advanced diagnostic tools to facilitate timely treatment initiation. Additionally, the rise of personalized medicine is reshaping the therapeutic landscape, driven by genetic insights and molecular diagnostics that cater to individual patient profiles. This trend is fostering the development of targeted therapies designed to address the unique variations in acute pancreatitis. Complementing these approaches, there is an increasing integration of digital health solutions and minimally invasive interventions, collectively aiming to streamline patient management and improve recovery rates. Overall, these market trends reflect a commitment to advancing the quality of care in acute pancreatitis treatment.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement

Global Acute Pancreatitis Market Size by Diagnosis & CAGR (2026-2033)

• Market Overview
• Imaging Tests
• Laboratory Tests

Global Acute Pancreatitis Market Size by Cause & CAGR (2026-2033)

• Market Overview
• Gallstones
• Alcohol
• Others

Global Acute Pancreatitis Market Size by Treatment & CAGR (2026-2033)

• Market Overview
• Intravenous fluid
• Nutritional support
• Analgesics
• Endoscopic Retrograde Cholangiopancreatography (ERCP)
• Others

Global Acute Pancreatitis Market Size by End user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Clinics
• Diagnostic Centers
• Others

Global Acute Pancreatitis Market Size & CAGR (2026-2033)

• North America (Diagnosis, Cause, Treatment, End user)
  • US
  • Canada
• Europe (Diagnosis, Cause, Treatment, End user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Diagnosis, Cause, Treatment, End user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Diagnosis, Cause, Treatment, End user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Diagnosis, Cause, Treatment, End user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Baxter International Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CalciMedica Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dynavax Technologies Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fresenius SE & Co. KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Olympus Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SCM Lifescience (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GNT Pharma Co. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boston Scientific Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceuticals (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• General Electric Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mitsubishi Tanabe Pharma Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations